First clinical study of new pediatric croup vaccine shows safety, tolerability...( Scientists at St. Jude Children's Resea...)

Scientists at St. Jude Children's Research Hospital are investigating in adults the use of a vaccine given by nose drops that might ultimately protect children against human parainfluenza virus-type 1 (hPIV-1). This virus is the most common cause of croup, a pediatric respiratory disease that causes almost 30,000 hospitalizations each year and many more emergency room visits.

These findings are published in the current issue of Vaccine.

Successful development of an effective hPIV-1 vaccine would be significant because none is currently available and a vaccine that is given to infants using nose drops would eliminate the discomfort and complications of injections.

Because the vaccine contains a live virus, it should stimulate both antibody and cellular immune responses, which together may provide durable protection from hPIV-1. In cellular immunity, special cells, rather than antibodies, destroy virus-infected cells inside the body.

The vaccine consists of Sendai virus (SeV), a mouse virus that is similar enough to hPIV-1 to act as a vaccine, but different enough to have never been associated with a human disease, according to Karen Slobod, M.D., associate member of the department of Infectious Diseases.

Slobod is the lead author of the Vaccine report.

Pre-clinical studies by the St. Jude team proved that intranasal SeV vaccine can protect against the human croup virus. The results of the study in nine healthy adults demonstrated that the SeV vaccine was safe and well tolerated. None of those vaccinated experienced any significant reactions, such as respiratory symptoms or laboratory abnormalities.

This FDA-approved Phase I trial was initiated in adults as a first step, prior to future testing in children and then infants--the ultimate target population, said Jerry Shenep, M.D., member of the department of Infectious Diseases and a co-author of the paper.

"The St. Jude team based the vaccine on SeV for two reasons," sai
'"/>

Contact: Bonnie Cameron
bonnie.cameron@stjude.org
901-495-4815
St. Jude Children's Research Hospital
23-Aug-2004

Page: 1 2
Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. 2nd media alert First Scientific Conference on Childhood Leukaemia
3. First International Scientific Conference on Childhood Leukaemia
4. First ever standards linking climate change, biodiversity and poverty seek global peer review
5. First genetic comparison of purebred domestic dogs produces surprises
6. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
7. First target for childhood malaria vaccine
8. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
9. First flavors form a lasting impression
10. STN International launches Derwent World Patents Index First View
11. First DFG research conference in the USA